{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihox64u74hfghs7ixlzhfv2dmzm4a7ksnvcyhudobosfaeklwb7ye",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mnne2p5xfsm2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiezv3c3mg2nfyrxlcfyojhq3dfpr74is3iyyb6hddmjwtzwndz5vi"
    },
    "mimeType": "image/jpeg",
    "size": 64211
  },
  "path": "/2026/06/06/illy-retatrutide-triple-g-weight-loss-obesity-safety-data-ada/?utm_campaign=rss",
  "publishedAt": "2026-06-06T18:32:27.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Pharma",
    "biotechnology",
    "chronic disease",
    "diabetes",
    "drug development",
    "Obesity",
    "Pharmaceuticals",
    "STAT+"
  ],
  "textContent": "Eli Lilly presented new safety and tolerability data on retatrutide at the annual meeting of the American Diabetes Association on Saturday.",
  "title": "STAT+: Lilly shares safety, tolerability data on its next-gen obesity drug",
  "updatedAt": "2026-06-06T18:55:33.000Z"
}